Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo

Bookmark and Share
Published: 19 Dec 2019
Views: 234
Rating:
Save
Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA

Dr Siddhartha Ganguly speaks to ecancer at the 2019 ASH meeting in Orlando about the Quantum-R trial evaluating clinical outcomes and characteristics of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemotherapy.

He explains that patients who had received quizartinib were much more likely to have received transplantation, this seemed to be due to the complete remission rate was much higher in the quizartinib arm giving them a window of opportunity to take them to the allergenic stem cell transplantation.

Dr Ganguly also reports that patients who received the transplant had a significant survival benefit over those that did not.